The effects of miglitol on glucagon‐like peptide‐1 secretion and appetite sensations in obese type 2 diabetics

Background: Previous studies reported that administration of first generation α‐glucosidase inhibitors (AGIs), such as voglibose or acarbose, produced exaggerated and sustained postprandial responses of glucagon‐like peptide‐1 (GLP‐1), an incretin hormone from the enteroinsular axis, in healthy humans. Little is known about the postprandial release of GLP‐1 after AGI therapy in diabetics. GLP‐1 plays a role to mediate satiety. Any agent that substantially elevates GLP‐1 levels may theoretically reduce hunger, increase satiation and limit food intake.

[1]  N. Read,et al.  The role of the gut in regulating food intake in man. , 2009, Nutrition reviews.

[2]  J. Holst,et al.  Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. , 1999, Diabetes care.

[3]  J. Wishart,et al.  Effects of age on concentrations of plasma cholecystokinin, glucagon-like peptide 1, and peptide YY and their relation to appetite and pyloric motility. , 1999, The American journal of clinical nutrition.

[4]  S. Rössner,et al.  Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. , 1999, International Journal of Obesity.

[5]  D Conen,et al.  Glucagon-like peptide-1: a potent regulator of food intake in humans , 1999, Gut.

[6]  J. Wishart,et al.  Interaction of insulin, glucagon-like peptide 1, gastric inhibitory polypeptide, and appetite in response to intraduodenal carbohydrate. , 1998, The American journal of clinical nutrition.

[7]  S. Rössner,et al.  Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. , 1998, The American journal of clinical nutrition.

[8]  J. Holst,et al.  Prolonged and enhanced secretion of glucagon‐like peptide 1 (7‐36 amide) after oral sucrose due to α‐glucosidase inhibition (acarbose) in Type 2 diabetic patients , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[9]  V. Marks,et al.  Delayed gastric emptying occurs following acarbose administration and is a further mechanism for its anti‐hyperglycaemic effect , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[10]  A. Astrup,et al.  Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. , 1998, The Journal of clinical investigation.

[11]  P. Geiselman,et al.  Control of food intake. A physiologically complex, motivated behavioral system. , 1996, Endocrinology and metabolism clinics of North America.

[12]  Lawrence A Leiter,et al.  The Effect of Acarbose on Insulin Sensitivity in Subjects With Impaired Glucose Tolerance , 1996, Diabetes Care.

[13]  Y. Hara,et al.  Improvement of insulin sensitivity and dyslipidemia with a new alpha-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects. , 1996, Metabolism: clinical and experimental.

[14]  V. Marks,et al.  Attenuated GLP-1 secretion in obesity: cause or consequence? , 1996, Gut.

[15]  P. J. Larsen,et al.  Distribution of GLP‐1 Binding Sites in the Rat Brain: Evidence that Exendin‐4 is a Ligand of Brain GLP‐1 Binding Sites , 1995, The European journal of neuroscience.

[16]  G. Bray,et al.  Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. , 1995, The American journal of medicine.

[17]  A. Astrup,et al.  The reproducibility of subjective appetite scores , 1995, British Journal of Nutrition.

[18]  J. Holst,et al.  Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. , 1994, Gastroenterology.

[19]  H. Holmsen.  Significance of testing platelet functions in vitro , 1994, European journal of clinical investigation.

[20]  V. Marks,et al.  GLP-1 SECRETION IN RESPONSE TO NUTRIENTS IN MAN , 1993 .

[21]  C. Ørskov.  Glucagon-like peptide-1, a new hormone of the entero-insular axis , 1992, Diabetologia.

[22]  C. Bailey.  Biguanides and NIDDM , 1992, Diabetes Care.

[23]  J. Olefsky,et al.  Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects , 1992, Diabetes Care.

[24]  S. Clissold,et al.  Acarbose: A Preliminary Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential , 1988 .

[25]  W. Creutzfeldt,et al.  Decreased GIP Secretion through Impairment of Absorption1 , 1980 .

[26]  H. Korsmo,et al.  The intestinal brush border membrane in diabetes. Studies of sucrase-isomaltase metabolism in rats with streptozotocin diabetes. , 1977, The Journal of clinical investigation.

[27]  J. Morley,et al.  Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. , 1998, Obesity research.

[28]  B. Göke,et al.  Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. , 1995, Digestion.

[29]  H. Bischoff.  Pharmacology of α-glucosidase inhibition , 1994 .

[30]  J. Holst,et al.  GLP-1 : a humoral mediator of the ileal brake in humans ? , 1993 .

[31]  P. Layer,et al.  Fate of pancreatic enzymes in the human intestinal lumen in health and pancreatic insufficiency. , 1993, Digestion.

[32]  R. Thirlby,et al.  Response of tGLP-1 to nutrients in humans , 1993 .

[33]  T. Matsuo,et al.  Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes. , 1992, The American journal of clinical nutrition.

[34]  C. Orskov.  Glucagon-like peptide-1, a new hormone of the entero-insular axis. , 1992, Diabetologia.

[35]  L. Sjöström,et al.  Relapse-Reducing Effects of Acarbose After Weight Reduction in Severely Obese Subjects , 1988 .

[36]  J. Holst,et al.  Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity. , 1983, International journal of obesity.